No Data
No Data
Gain Therapeutics Says Australia Approves Start of Phase 1b Parkinson's Disease Study
Express News | Gain Therapeutics Inc - Enrollment Expected to Complete in Spring 2025, Data Expected Mid-2025
Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People With GBA1 and Idiopathic Parkinson's Disease
Express News | Gain Therapeutics Initiates Phase 1B Clinical Trial of Lead Candidate GT-02287 in People With Gba1 and Idiopathic Parkinson’s Disease
Gain Therapeutics To Present At Biotech Showcase 2025
H.C. Wainwright Maintains Gain Therapeutics(GANX.US) With Buy Rating, Cuts Target Price to $7